An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: Is the different toxicity profile clinically relevant?

Infection

Volumn 36, Issue 1, 2008, Pages 54-58

  Hahn Ast, C ^a   Glasmacher, A ^a   Arns, A ^a   Muhling A ^a   Orlopp, K ^a   Marklein, G ^a   Von Lilienfeld Toal, M ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CEFTRIAXONE; CYCLOSPORIN A; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOXICITY; FEBRILE NEUTROPENIA; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ANTI-BACTERIAL AGENTS; CREATINE; DRUG THERAPY, COMBINATION; FEMALE; FEVER; FEVER OF UNKNOWN ORIGIN; HUMANS; INFECTION; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; TEICOPLANIN; VANCOMYCIN;

EID: 43049177742     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-7126-4     Document Type: Article

References (12)

1. Smith SR, Cheesebrough J, Spearing R, Davies JM: Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 1989; 33: 1193-1197.
2. Menichetti F, Martino P, Bucaneve G, Gentile G, D'Antonio D, Liso V, Ricci P, Nosari AM, Buelli M, Carotenuto M, Fasola G, Jacopino P, Montillo M, Barbabietola G, Girmenia C, Del Favero A: Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Antimicrob Agents Chemother 1994; 38: 2041-2046.
3. Rolston KVI, Nguyen H, Amos G, Elting L, Fainstein V, Bodey GP: A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 1994; 169: 350-355.
4. Neville LO, Brumfit W, Hamilton-Miller JMT, Harding I: Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. Intern J Antimicrob Agents 1995; 5: 187-193.
5. Chow AW: Teicoplanin versus Vancomycin zur empirischen Therapie bei neutropenischen Patienten mit Fieber. Eur J Haematol 1993; 51: 18-24.
6. Wood MJ: The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-222.
7. Vazquez L, Encinas MP, Morin LS, Vilches P, Gutierrez N, Garcia-Sanz R, Caballero D, Hurle AD, San Miguel JF: Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Haematologica 1999; 84: 231-236.
8. Kureishi A, Jewesson PJ, Rubinger M, Cole CD, Reece DE, Phillips GL, Smith JA, Chow AW: Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991; 35: 2246-2252.
9. Bucaneve G, Menichetti F, Del Favero A: Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia. Pharmacoeconomics 1999; 15: 85-95.
10. Cony-Makhoul P, Brossard G, Marit G, Pellegrin JL, Texier-Maugein J, Reiffers J: A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol 1990; 76: 35-40.
11. Cometta A, Kern WV, de Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382-389.
12. Erjavec Z, Vries-Hospers HG, Laseur M, Halie RM, Daenen S: A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000; 45: 843-849.